Related references
Note: Only part of the references are listed.Doxorubicin targets multiple players: A new view of an old problem
Donato Cappetta et al.
PHARMACOLOGICAL RESEARCH (2018)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
Jose Luis Zamorano et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity
Donato Cappetta et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice
Francesca Molinari et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2017)
Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction
Donato Cappetta et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib
Samantha J. Cushen et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer
Stefania Mantarro et al.
INTERNAL AND EMERGENCY MEDICINE (2016)
Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction
Laura A. A. Gilliam et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?
James C. Sorensen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction
Antonella De Angelis et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Animal models of cardiac cachexia
Francesca Molinari et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy
Donato Cappetta et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle (vol 6, pg 3043, 2015)
Francesca Pretto et al.
ONCOTARGET (2016)
Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
Gennaro Riccio et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine
Elisabetta Ferraro et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2016)
mtDNA damage in the development of heart failure
Alyssa A. Lombardi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Impaired dynamics and function of mitochondria caused by mtDNA toxicity leads to heart failure
Knut H. Lauritzen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Apaf1-deficient cortical neurons exhibit defects in axonal outgrowth
Daniela De Zio et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Muscle wasting in cancer: the role of mitochondria
Josep M. Argiles et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2015)
SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells
Antonella De Angelis et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy
Kisuk Min et al.
JOURNAL OF PHYSIOLOGY-LONDON (2015)
Skeletal Muscle an Active Compartment in the Sequestering and Metabolism of Doxorubicin Chemotherapy
Sergio Fabris et al.
PLOS ONE (2015)
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction
Carlo G. Tocchetti et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
Tomáš Šimůnek et al.
Pharmacological Reports (2014)
Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A
Amy D. Hanna et al.
MOLECULAR PHARMACOLOGY (2014)
Trastuzumab-containing regimens for metastatic breast cancer
Sara Balduzzi et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection
Martin Sterba et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
O. Huillard et al.
BRITISH JOURNAL OF CANCER (2013)
The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes
Elisabetta Ferraro et al.
FEBS JOURNAL (2013)
Mitochondrial dysfunction mediated cisplatin induced toxicity: Modulatory role of curcumin
Mohammad Waseem et al.
FOOD AND CHEMICAL TOXICOLOGY (2013)
The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle
Laura A. A. Gilliam et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function
Reid Hayward et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2013)
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
Adrian S. Dobs et al.
LANCET ONCOLOGY (2013)
Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study
Martina Bonifazi et al.
ONCOLOGIST (2013)
Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore
M. Gharanei et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
Mitochondria: gatekeepers of response to chemotherapy
Kristopher A. Sarosiek et al.
TRENDS IN CELL BIOLOGY (2013)
After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lynnphoblastic leukemia in childhood
Celena Scheede-Bergdahl et al.
FRONTIERS IN PHARMACOLOGY (2013)
The Novel Anthracenedione, Pixantrone, Lacks Redox Activity and Inhibits Doxorubicinol Formation in Human Myocardium: Insight to Explain the Cardiac Safety of Pixantrone in Doxorubicin-Treated Patients
Emanuela Salvatorelli et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes
Laura A. A. Gilliam et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Yanti Octavia et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects
Steen Larsen et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
Erin J. Aiello Bowles et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Effects of a home-based exercise program on metabolic risk factors and fitness in long-term survivors of childhood acute lymphoblastic leukemia
Liisa S. Jarvela et al.
PEDIATRIC BLOOD & CANCER (2012)
Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism
Yan Ding et al.
NATURE COMMUNICATIONS (2012)
Trastuzumab containing regimens for early breast cancer
Lorenzo Moja et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Mitochondria Death/Survival Signaling Pathways in Cardiotoxicity Induced by Anthracyclines and Anticancer-Targeted Therapies
David Montaigne et al.
BIOCHEMISTRY RESEARCH INTERNATIONAL (2012)
Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. II. Amrubicin Shows Metabolic Advantages over Doxorubicin and Epirubicin
Emanuela Salvatorelli et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Drug-Induced Oxidative Stress and Toxicity
Damian G. Deavall et al.
JOURNAL OF TOXICOLOGY (2012)
Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress
Laura A. A. Gilliam et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
The DNA repair complex Ku70/86 modulates Apaf1 expression upon DNA damage
D. De Zio et al.
CELL DEATH AND DIFFERENTIATION (2011)
PARP-2 Regulates SIRT1 Expression and Whole-Body Energy Expenditure
Peter Bai et al.
CELL METABOLISM (2011)
PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation
Peter Bai et al.
CELL METABOLISM (2011)
Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models
Colin F. Greineder et al.
CURRENT HYPERTENSION REPORTS (2011)
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
Thomas Eschenhagen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2011)
Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle
Ashley J. Smuder et al.
JOURNAL OF APPLIED PHYSIOLOGY (2011)
DOXORUBICIN CAUSES DIAPHRAGM WEAKNESS IN MURINE MODELS OF CANCER CHEMOTHERAPY
Laura A. A. Gilliam et al.
MUSCLE & NERVE (2011)
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors
Adriana Albini et al.
FUTURE CARDIOLOGY (2011)
Emerging role of neuregulin as a modulator of muscle metabolism
Anna Guma et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
The sites and topology of mitochondrial superoxide production
Martin D. Brand
EXPERIMENTAL GERONTOLOGY (2010)
Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy
Nicola Maurea et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2010)
Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
Vishnu Chintalgattu et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Michael S. Ewer et al.
NATURE REVIEWS CARDIOLOGY (2010)
Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?
Douglas B. Sawyer et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2010)
Autophagy plays an important role in Sunitinib-mediated cell death in H9c2 cardiac muscle cells
Yuqin Zhao et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity
Brian B. Hasinoff
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
How mitochondria produce reactive oxygen species
Michael P. Murphy
BIOCHEMICAL JOURNAL (2009)
Direct effects of doxorubicin on skeletal muscle contribute to fatigue
K. van Norren et al.
BRITISH JOURNAL OF CANCER (2009)
Trastuzumab versus lapatinib: The cardiac side of the story
Hamdy Azim et al.
CANCER TREATMENT REVIEWS (2009)
Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors
Shao-Chun Wang et al.
CLINICAL CANCER RESEARCH (2009)
Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase
Risto Kerkela et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2009)
Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle
Laura A. A. Gilliam et al.
JOURNAL OF APPLIED PHYSIOLOGY (2009)
Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways
Leo I. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth
Y. H. Zhao et al.
ONCOGENE (2009)
Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes
Yasuhiro Yamamoto et al.
CARDIOVASCULAR RESEARCH (2008)
AMP Activated Protein Kinase-α2 Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction in Mice
Ping Zhang et al.
HYPERTENSION (2008)
Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib
Brian B. Hasinoff et al.
MOLECULAR PHARMACOLOGY (2008)
Exercise-induced oxidative stress: Cellular mechanisms and impact on muscle force production
Scott K. Powers et al.
PHYSIOLOGICAL REVIEWS (2008)
Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix
Marc Niere et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia
Kirsten K. Ness et al.
PEDIATRIC BLOOD & CANCER (2007)
Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
Gustavo A. Viani et al.
BMC CANCER (2007)
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells
Neil L. Spector et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Collateral damage in cancer chemotherapy - Oxidative stress in nontargeted tissues
Yumin Chen et al.
MOLECULAR INTERVENTIONS (2007)
Free radical-mediated skeletal muscle dysfunction in inflammatory conditions
Gerald S. Supinski et al.
JOURNAL OF APPLIED PHYSIOLOGY (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Exercise-induced cardioprotection - biochemical, morphological and functional evidence in whole tissue and isolated mitochondria
Antonio Ascensao et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2007)
AMP-activated protein kinase in the heart - Role during health and disease
Michael Arad et al.
CIRCULATION RESEARCH (2007)
Anthracycline cardiotoxicity in long-term survivors of childhood cancer
Rebecca E. Scully et al.
CARDIOVASCULAR TOXICOLOGY (2007)
erbB2 is required for G protein-coupled receptor signaling in the heart
Alejandra Negro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Apoptosome impairment during development results in activation of an autophagy program in cerebral cortex
Sandra Moreno et al.
APOPTOSIS (2006)
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience
Valentina Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase
Ye Xiong et al.
FREE RADICAL BIOLOGY AND MEDICINE (2006)
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Malgorzata Tokarska-Schlattner et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress
K Terai et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls
KL Syrjala et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis
A Ascensao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Caspase-3 dependent cleavage and activation of skeletal muscle phosphorylase b kinase
TL Hilder et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2005)
The cardiotoxicology of anthracycline chemotherapeutics: Translating molecular mechanism into preventative medicine
XY Peng et al.
MOLECULAR INTERVENTIONS (2005)
Mechanisms of disuse muscle atrophy: role of oxidative stress
SK Powers et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Clinical cardiac tolerability of trastuzumab
EA Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells
J Kluza et al.
ONCOGENE (2004)
Exercise issues in older cancer survivors
KS Courneya et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2004)
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiornyocytes - Implications for herceptin-induced cardiomyopathy
LP Grazette et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Alkylating DNA damage stimulates a regulated form of necrotic cell death
WX Zong et al.
GENES & DEVELOPMENT (2004)
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4
HE Mohamed et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy
D Lebrecht et al.
CIRCULATION (2003)
NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes
WH Ying et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise
DL Coven et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
Induction or suppression of expression of cytochrome C oxidase subunit II by heregulin β 1 in human mammary epithelial cells is dependent on the levels of ErbB2 expression
YB Sun et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
C Özcelik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
ErbB2 is essential in the prevention of dilated cardiomyopathy
SA Crone et al.
NATURE MEDICINE (2002)
Early changes in myocardial antioxidant enzymes in rats treated with adriamycin
T Li et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2002)
Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy
MM Sayed-Ahmed et al.
PHARMACOLOGY & TOXICOLOGY (2001)
Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14-3-3-dependent and 14-3-3-independent pathways
CM Cahill et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
